NCR1 and colorectal carcinoma: Separate addition of anti-NKp46, anti-DNAM-1, or anti-NKG2D mAbs decreased CRC cell lysis; the addition of anti-NKp30 mAb induced the highest percentage of inhibition (35.70 ± 4.95%).